FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W46453237> ?p ?o ?g. }

• W46453237 endingPage "622" @default.
• W46453237 startingPage "616" @default.
• W46453237 abstract "Abstract Treatment with alkylating agents or radiophosphorous (32P) has been shown to carry a certain leukemogenic risk in myeloproliferative disorders (MPDs), including essential thrombocytemia (ET). The leukemogenic risk associated to treatment with hydroxyurea in ET, on the other hand, is generally considered to be relatively low. Between 1970 and 1991, we diagnosed ET in 357 patients, who were monitored until 1996. One or several therapeutic agents had been admistered to 326 patients, including hydroxyurea (HU) in 251 (as only treatment in 201), pipobroman in 43, busulfan in 41, and32P in 40. With a median follow-up duration of 98 months, 17 patients (4.5%) had progressed to acute myeloid leukemia (AML; six cases) or myelodysplastic syndrome (MDS; 11 cases). Fourteen of these patients had received HU, as sole treatment in seven cases, and preceded or followed by other treatment in seven cases, mainly pipobroman (five cases). The remaining three leukemic progressions occurred in patients treated with 32P (two cases) and busulfan (one case). The incidence of AML and MDS after treatment, using 32P alone and 32P with other agents, busulfan alone and with other agents, HU alone and with others agents, and pipobroman alone and with other agents was 7% and 9%, 3% and 17%, 3.5% and 14%, and 0% and 16%, respectively. Thirteen of 17 patients who progressed to AML or MDS had successful cytogenetic analysis. Seven of them had rearrangements of chromosome 17 (unbalanced translocation, partial or complete deletion, isochromosome 17q) that resulted in 17p deletion. They also had a typical form of dysgranulopoiesis combining pseudo Pelger Hüet hypolobulation and vacuoles in neutrophils, and p53 mutation, as previously described in AML and MDS with 17p deletion. Those seven patients had all received HU, as the only therapeutic agent in three, and followed by pipobroman in three. The three patients who had received no HU and progressed to AML or MDS had no 17p deletion. A review of the literature found cytogenetic analysis in 35 cases of AML and MDS occurring after ET, 11 of whom had been treated with HU alone. Five of 35 patients had rearrangements that resulted in 17p deletion. Four of them had been treated with HU alone. These results show that treatment with HU alone is associated with a leukemic risk of approximately 3.5%. A high proportion of AML and MDS occurring in ET treated with HU (alone or possibly followed by pipobroman) have morphologic, cytogenetic, and molecular characteristics of the 17p− syndrome. These findings suggest that widespread and prolonged use of HU in ET may have to be reconsidered in some situations, such as asymptomatic ET." @default.
• W46453237 created "2016-06-24" @default.
• W46453237 creator A5009368373 @default.
• W46453237 creator A5014838075 @default.
• W46453237 creator A5018416096 @default.
• W46453237 creator A5027242467 @default.
• W46453237 creator A5053031492 @default.
• W46453237 creator A5064550207 @default.
• W46453237 creator A5064920084 @default.
• W46453237 creator A5067797551 @default.
• W46453237 creator A5088794779 @default.
• W46453237 date "1998-01-15" @default.
• W46453237 modified "2023-10-18" @default.
• W46453237 title "Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p Deletion" @default.
• W46453237 cites W103382957 @default.
• W46453237 cites W1446966563 @default.
• W46453237 cites W1548342317 @default.
• W46453237 cites W1571376117 @default.
• W46453237 cites W1928343029 @default.
• W46453237 cites W1968141346 @default.
• W46453237 cites W1977053478 @default.
• W46453237 cites W1977474358 @default.
• W46453237 cites W1980029052 @default.
• W46453237 cites W1995607351 @default.
• W46453237 cites W2009955884 @default.
• W46453237 cites W2024482804 @default.
• W46453237 cites W2024550450 @default.
• W46453237 cites W2032345724 @default.
• W46453237 cites W2033303986 @default.
• W46453237 cites W2033946159 @default.
• W46453237 cites W2036143671 @default.
• W46453237 cites W2036508454 @default.
• W46453237 cites W2037399360 @default.
• W46453237 cites W2049538784 @default.
• W46453237 cites W2052905336 @default.
• W46453237 cites W2057427886 @default.
• W46453237 cites W2057704321 @default.
• W46453237 cites W2069818961 @default.
• W46453237 cites W2071808385 @default.
• W46453237 cites W2071809070 @default.
• W46453237 cites W2073979835 @default.
• W46453237 cites W2076689289 @default.
• W46453237 cites W2077969468 @default.
• W46453237 cites W2079569718 @default.
• W46453237 cites W2079873385 @default.
• W46453237 cites W2086608011 @default.
• W46453237 cites W2087623186 @default.
• W46453237 cites W2092298450 @default.
• W46453237 cites W2098259389 @default.
• W46453237 cites W2117054170 @default.
• W46453237 cites W2320032845 @default.
• W46453237 cites W2329964205 @default.
• W46453237 cites W2399669199 @default.
• W46453237 cites W266774159 @default.
• W46453237 cites W308074524 @default.
• W46453237 cites W3140027046 @default.
• W46453237 cites W4253916874 @default.
• W46453237 cites W80989898 @default.
• W46453237 cites W99703884 @default.
• W46453237 cites W2042894289 @default.
• W46453237 cites W2092963804 @default.
• W46453237 cites W2331399485 @default.
• W46453237 doi "https://doi.org/10.1182/blood.v91.2.616" @default.
• W46453237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9427717" @default.
• W46453237 hasPublicationYear "1998" @default.
• W46453237 type Work @default.
• W46453237 sameAs 46453237 @default.
• W46453237 citedByCount "351" @default.
• W46453237 countsByYear W464532372012 @default.
• W46453237 countsByYear W464532372013 @default.
• W46453237 countsByYear W464532372014 @default.
• W46453237 countsByYear W464532372015 @default.
• W46453237 countsByYear W464532372016 @default.
• W46453237 countsByYear W464532372017 @default.
• W46453237 countsByYear W464532372018 @default.
• W46453237 countsByYear W464532372019 @default.
• W46453237 countsByYear W464532372020 @default.
• W46453237 countsByYear W464532372021 @default.
• W46453237 countsByYear W464532372022 @default.
• W46453237 crossrefType "journal-article" @default.
• W46453237 hasAuthorship W46453237A5009368373 @default.
• W46453237 hasAuthorship W46453237A5014838075 @default.
• W46453237 hasAuthorship W46453237A5018416096 @default.
• W46453237 hasAuthorship W46453237A5027242467 @default.
• W46453237 hasAuthorship W46453237A5053031492 @default.
• W46453237 hasAuthorship W46453237A5064550207 @default.
• W46453237 hasAuthorship W46453237A5064920084 @default.
• W46453237 hasAuthorship W46453237A5067797551 @default.
• W46453237 hasAuthorship W46453237A5088794779 @default.
• W46453237 hasBestOaLocation W464532371 @default.
• W46453237 hasConcept C104317684 @default.
• W46453237 hasConcept C126322002 @default.
• W46453237 hasConcept C2776694085 @default.
• W46453237 hasConcept C2776755627 @default.
• W46453237 hasConcept C2778461978 @default.
• W46453237 hasConcept C2778729363 @default.
• W46453237 hasConcept C2778837598 @default.
• W46453237 hasConcept C2779282312 @default.

• next